好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Overlapping and Distinguishing Neuroimaging Features of the Central Nervous System Demyelinating Disorders: MS, NMOSD, and MOGAD
Multiple Sclerosis
P8 - Poster Session 8 (5:30 PM-6:30 PM)
6-002

To describe and identify the overlapping and distinguishing neuroimaging features among MS, NMOSD, and MOGAD syndromes.

In the era of the enlarging spectrum of MS and other antibody-associated demyelinating syndromes, there remain some cases with overlapping neuroimaging features that cause diagnostic and therapeutic challenges. In this context, the main diagnostic marker is the serological status of the patients. To fill this diagnostic gap, further research is warranted for better distinguishing neuroimaging markers in the lack of antibody testing.

A total of 204 MS patients fulfilling the McDonald 2017 criteria, 36 AQP4-IgG+ and 21 double-seronegative NMOSD patients fulfilling the 2015 diagnostic criteria for NMOSD, and 15 MOGAD patients fulfilling the 2023 MOGAD Panel proposed criteria were included. Demographic features and neuroimaging findings of the four groups were retrospectively evaluated.

Female ratios were 69.6% in the MS, 94.4% in the AQP4+NMOSD, 76.2% in the seronegative NMOSD, and 33.3% in the MOGAD groups. Temporal periventricular lesions were significantly higher in the MOGAD group than in the AQP4-IgG+ and seronegative NMOSD groups (p=0.02 for both). Cerebellar peduncle lesions were significantly higher in the MOGAD group compared with the AQP4-IgG+ NMOSD group (p=0.07). Longitudinally-extensive spinal cord lesions were significantly higher in AQP4-IgG+ and seronegative NMOSD groups than in the MOGAD group (p=0.01 and p=0.001, respectively). There was no statistically significant difference between the proportion of longitudinally-extensive optic neuritis lesions between the NMOSD and MOGAD groups. Spinal atrophy was significantly lower in the MOGAD group compared with the AQP4-IgG+ and seronegative NMOSD groups (p=0.03 and p=0.04, respectively).

Although the diagnostic criteria for MS and NMOSD are available and were also recently proposed for MOGAD, the neuroimaging features of these disorders may be strikingly similar. To overcome this diagnostic uncertainty, overlapping and distinguishing neuroimaging features of CNS disorders should be investigated more thoroughly.

Authors/Disclosures
Bade Gulec
PRESENTER
Bade Gulec has nothing to disclose.
Elif Everest, PhD (National Institutes of Health) Ms. Everest has received personal compensation in the range of $50,000-$99,999 for serving as a postdoctoral visiting fellow with National Institutes of Health.
Samet Cam No disclosure on file
Melih Tutuncu, MD (ISTANBUL UNIVERSITESI CERRAHPASA TIP FAKULTESI) Dr. Tutuncu has nothing to disclose.
Ugur Uygunoglu (Cerrahpasa) Ugur Uygunoglu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Turkey . The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen Idec/Gen Pharma of Turkey. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck-Serono of Turkey. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanovel of Turkey. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Genveon of Turkey.
Sabahattin Saip Sabahattin Saip has nothing to disclose.
Aksel Siva, MD (Istanbul University Cerrahpasa School of Medicine) Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen - TR. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ali Raif Pharmaceuticals, Turkiye. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanovel Pharmaceuticals, Turkiye. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abdi Ibrahim Ilac - TR. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck Serono . The institution of Dr. Siva has received research support from Turkish MS Society. The institution of Dr. Siva has received research support from The Scientific and Technological Research Council Of Turkey - Health Sciences Research Grants.